Valion Bio Appoints Dean Zikria as Interim CEO Amid Board Overhaul
VBIO sits 24% above its 52-week low of $2.05.
Summary
Valion Bio appointed board member Dean Zikria as Interim CEO and overhauled its board leadership, with compensation tied to closing a strategic transaction.
Key Events · Executive and Board Changes · VBIO
-
Interim CEO Appointed
Dean Zikria, a board member since 2019, was appointed Interim CEO effective September 22, 2026, replacing the CEO terminated on August 17.
-
Compensation Tied to Strategic Deal
Zikria's consulting agreement pays $23,333 monthly plus 50,000 RSUs, with another 50,000 RSUs contingent on shareholder approval and a cash bonus upon closing a reverse merger, merger, or acquisition.
-
Board Leadership Overhaul
Sheryle Bolton resigned from the Board effective September 17; Thomas Jensen was appointed Chair and Compensation Committee Chair, and Jared Malbin was appointed Audit and Risk Committee Chair.
-
Committee Independence Changes
Zikria was removed from the Audit, Compensation, and Nominations committees while serving as Interim CEO, reflecting his non-independent status.
Analysis · VBIO · Life Sciences
Valion Bio has installed board member Dean Zikria as Interim CEO, filling the leadership vacuum left by the August 17 termination of its prior CEO. The move comes as the company faces going-concern doubt, a depleted cash position, and an activist investor that has already taken control of the board. Zikria's consulting agreement pays $23,333 monthly plus up to 100,000 RSUs, with a cash bonus tied to closing a strategic transaction — a clear signal the board is prioritizing a reverse merger or acquisition. The simultaneous resignation of Chair Sheryle Bolton and the appointment of Thomas Jensen as Chair and Jared Malbin as Audit Chair consolidate control under the activist-aligned faction. For a company with a $2.2 million market cap and $2.1 million in cash, this leadership reset is a pivotal governance event that could determine whether Valion survives as an independent entity.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $2.05 to $78.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.